CFDE Data Portal | Search PGM5P2

	Label	Description
	PGM5P2 associations Collection (Entity type)	Associations for PGM5P2_associations
	PGM5P2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	PGM5P2 Gene (Entity type)	ENSG00000290923 - phosphoglucomutase 5 pseudogene 2
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 3 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 7 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 8 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 6 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236896 GSE237665 DNMT EZH2 inhibition 6 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

PGM5P2 associations

Associations for PGM5P2_associations

PGM5P2 associations.tsv

A file from IDG as part of the Harmonizome project

PGM5P2

ENSG00000290923 - phosphoglucomutase 5 pseudogene 2

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE146358 dopamine 3 v 7 human dn

A Gene Set from LINCS

GSE239844 crizotinib 7 v 0 human up

A Gene Set from LINCS

GSE239844 crizotinib 8 v 0 human up

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

A Gene Set from LINCS

GSE195568 palbociclib 6 v 10 human up

A Gene Set from LINCS

GSE236896 GSE237665 DNMT EZH2 inhibition 6 v 2 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.